Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease
Journal of Clinical Lipidology · 2023-11 · 17 (6) · 748-755
DOI: 10.1016/j.jacl.2023.09.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2023-11. Verfasst von Gregory A Panza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hartford Healthcare, Hartford, CT (Drs Panza, Tortora, Saucier, Fernandez). Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atherosclerosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Lipoprotein(a) [Lp(a)] is a genetically determined independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease. Despite recommendations from professional societies in the cardiovascular field, the awareness of elevated Lp(a) as a risk factor and screening for Lp(a) are suspected to be low. METHODS: We conducted a retrospective, observational case control study of patient charts from January 1, 2017 to June 19, 2022. The primary aims were 1) to describe the proportion of patients at the healthcare network's primary care and cardiology clinics that met Lp(a) screening criteria and were tested; and 2) to describe the proportion of patients throughout the entire healthcare network that had Lp(a) measured. RESULTS: Of the 2,412,020 patient charts in the health network, only 5,942 (0.25 %) had Lp(a) measured. Of the 84,581 patients in primary care or cardiology clinics who met screening criteria, only 1,311 (1.55 %) had Lp(a) measured. Patients with Lp(a) measured were more likely to be younger, non-Hispanic/Latinx, had a lipid panel measured, a cardiac computed tomography (CT) imaging study, and higher low-density lipoprotein-cholesterol. Patients with ASCVD, heart failure, ischemic heart disease, aortic stenosis, peripheral vascular disease, or a stroke did not feature highly among patients who received Lp(a) testing. Having an abnormal or risk-enhancing Lp(a) level was associated with being female and/or being Black/African American. CONCLUSIONS: Despite increased awareness of Lp(a) and its contribution to cardiovascular disease there exists a paucity of testing. Increased Lp(a) testing can identify patients who have an increased cardiovascular risk underestimated by other metrics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hartford Healthcare, Hartford, CT (Drs Panza, Tortora, Saucier, Fernandez).
- University of Chicago School of Medicine, Chicago, IL (Dr Blazek).
- Hartford Healthcare, Hartford, CT (Drs Panza, Tortora, Saucier, Fernandez). Electronic address: Antonio.Fernandez@hhchealth.org.
Zitieren
APA
Panza, G. A., Blazek, O., Tortora, J., Saucier, S., & Fernandez, A. B. (2023). Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease. Journal of Clinical Lipidology, 17(6), 748-755. https://doi.org/10.1016/j.jacl.2023.09.016
Vancouver
Panza GA, Blazek O, Tortora J, Saucier S, Fernandez AB. Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease. Journal of Clinical Lipidology. 2023;17(6):748-755. doi:10.1016/j.jacl.2023.09.016
BibTeX
@article{Panza2023,
author = {Panza, Gregory A and Blazek, Olivia and Tortora, Joseph and Saucier, Stephanie and Fernandez, Antonio B},
title = {Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease},
journal = {Journal of Clinical Lipidology},
year = {2023},
volume = {17},
number = {6},
pages = {748--755},
doi = {10.1016/j.jacl.2023.09.016}
}
EUVIMED